白三烯及其受体拮抗剂在肺部疾病中作用的研究进展  

Research progress of leukotrienes and leukotriene receptor antagonists in pulmonary diseases

作　　者：吴华[1] 陈筱青[1] 

机构地区：[1]南京医科大学第一附属医院儿科,210029

出　　处：《中华妇幼临床医学杂志（电子版）》2017年第2期234-239,共6页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：国家自然科学基金青年科学基金项目(81300521);江苏省六大高峰人才项目(WSN-090)~~

摘　　要：白三烯是花生四烯酸经5-脂氧合酶代谢途径形成的具有高度生物活性的代谢产物,是重要的炎症介质。研究结果表明,白三烯参与了支气管哮喘、慢性阻塞性肺疾病(COPD)、毛细支气管炎、支气管肺发育不良(BPD)及急性肺损伤(ALI)等多种肺部疾病的病理生理过程。白三烯通过与靶细胞膜上的受体结合而发挥致炎作用,故白三烯受体拮抗剂(LTRA)可通过与白三烯受体竞争性结合而起到抗炎作用,在改善肺功能、降低气道高反应性、抑制气道重塑及抗肺纤维化中发挥重要作用。近年研究结果显示,LTRA还具有重要的非受体依赖性抗炎作用。笔者拟就白三烯和LTRA在肺部疾病中作用的研究进展进行综述,为肺部疾病的治疗提供新思路。Leukotrienes are important inflammatory mediators derived from arachidonic acid through the 5-lipoxygenase pathway. Leukotrienes are implicated in the pathogenesis of many kinds of pulmonary diseases, including asthma, chronic obstructive pulmonary disease （COPD）, bronchiolitis, bronchopulmonary dysplasia （BPD） and acute lung injury （ALI）, etc.. Leukotrienes exert multiple biological effects by binding to cognate cell-surface receptors and leukotriene receptor antagonists （LTRA） produce their anti-inflammatory effects by competitively combining with leukotriene receptors, playing an important role in improving pulmonary function, decreasing airway hyperresponsiveness, inhibiting airway remodeling and pulmonary fibrosis. Anti-inflammatory activities of LTRA independent of leukotriene receptors have recently been suggested in recent researches. This review discusses the research progress of leukotrienes and the application of LTRA in pulmonary diseases, thus providing new ways for the treatment of pulmonary diseases.

关 键 词：白三烯类 白三烯受体拮抗剂 肺疾病 炎症 

分 类 号：R563[医药卫生—呼吸系统]